The Feminina Group, Inc.

Form 483 issued March 14, 2018 · Seattle, Washington

Inspection
Mar 8 – Mar 14, 2018
Observations
3
Pages
5
FEI number
3003363230

In short: On March 14, 2018, FDA issued a Form 483 with 3 observations to The Feminina Group, Inc. in Seattle, Washington (FEI 3003363230) after an inspection that ran Mar 8 – Mar 14, 2018. The investigators were Christopher S. Genther and Stephen R. Souza. Most observations concern cAPA; the most-cited regulation is 21 CFR 803.17 (what are the requirements for developing, maintaining, and implementing written MDR procedures that apply to me?).

At a glance

2 of 2 observations on this 483 concern capa.

CAPA2

Most cited: 21 CFR 803.17 (1×) · 820.198(a) (1×)

What FDA observed

Preview: the opening words of each observation
  1. 01

    Written MDR procedures have…

  2. 02

    Procedures for receiving, reviewing, and evaluating complaints by a formally designated unit have…

1 more observation

Plus the full detail behind each one, exactly as FDA wrote it.

Get the full 483

This inspection in context

Questions about this 483

What did FDA find at The Feminina Group, Inc.?

FDA listed 3 observations on this Form 483, mostly about cAPA. The most-cited regulation is 21 CFR 803.17 (what are the requirements for developing, maintaining, and implementing written MDR procedures that apply to me?). The opening words of each observation are shown on this page.

Who inspected The Feminina Group, Inc.?

Christopher S. Genther and Stephen R. Souza are named on this Form 483, for the inspection of Mar 8 – Mar 14, 2018. Each investigator has a profile showing what they cite most.

When was The Feminina Group, Inc. inspected by FDA?

The inspection ran Mar 8 – Mar 14, 2018, and the Form 483 is dated March 14, 2018.

How do I get the full Form 483 for The Feminina Group, Inc.?

Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.

$99Get it free